NO20072887L - Forbindelser og sammensetninger som protein kinase inhibitorer - Google Patents
Forbindelser og sammensetninger som protein kinase inhibitorerInfo
- Publication number
- NO20072887L NO20072887L NO20072887A NO20072887A NO20072887L NO 20072887 L NO20072887 L NO 20072887L NO 20072887 A NO20072887 A NO 20072887A NO 20072887 A NO20072887 A NO 20072887A NO 20072887 L NO20072887 L NO 20072887L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- compositions
- protein kinase
- kinase inhibitors
- met
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 abstract 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 abstract 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 abstract 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 abstract 1
- -1 MET Proteins 0.000 abstract 1
- 101100262697 Mus musculus Axl gene Proteins 0.000 abstract 1
- 101100272634 Mus musculus Bmx gene Proteins 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
- 101150111783 NTRK1 gene Proteins 0.000 abstract 1
- 101150117329 NTRK3 gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 abstract 1
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 abstract 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 abstract 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 abstract 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000005441 aurora Substances 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
Abstract
Oppfinnelsen tilveiebringer en ny klasse forbindelser, farmasøytiske sammensetninger som innbefatter slike forbindelser og fremgangsmåter for anvendelse av slike forbindelser for å behandle eller hindre sykdommer eller forstyrrelser assosiert med abnormal eller deregulert kinaseaktivitet, særlig sykdommer eller forstyrrelser som involverer abnormal aktivering av Abl-, Bcr-Abl-, cSrc-, TPR-Met-, Tie2-, MET-, FGFR3-, Aurora-, Axl-, Bmx-, BTK-, c-kit-, CHK2-, Flt3-, MST2-, p70S6K-, PDGFR-, PKB-, PKC-, Raf-, ROCK-II-, RskI-, SGK-, TrkA-, TrkB- og TrkC-kinaser.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62678504P | 2004-11-09 | 2004-11-09 | |
| US70964805P | 2005-08-19 | 2005-08-19 | |
| PCT/US2005/040372 WO2006052936A2 (en) | 2004-11-09 | 2005-11-07 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072887L true NO20072887L (no) | 2007-08-03 |
Family
ID=36337126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072887A NO20072887L (no) | 2004-11-09 | 2007-06-06 | Forbindelser og sammensetninger som protein kinase inhibitorer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8101608B2 (no) |
| EP (1) | EP1814545A4 (no) |
| JP (1) | JP4917041B2 (no) |
| KR (1) | KR20070084066A (no) |
| AR (1) | AR053652A1 (no) |
| AU (1) | AU2005304719B2 (no) |
| BR (1) | BRPI0517968A (no) |
| CA (1) | CA2583737C (no) |
| GT (1) | GT200500321A (no) |
| IL (1) | IL182687A0 (no) |
| MA (1) | MA29216B1 (no) |
| MX (1) | MX2007005547A (no) |
| NO (1) | NO20072887L (no) |
| RU (1) | RU2406725C2 (no) |
| TN (1) | TNSN07176A1 (no) |
| TW (1) | TW200631577A (no) |
| WO (1) | WO2006052936A2 (no) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| DE602005024599D1 (de) | 2004-10-25 | 2010-12-16 | Ligand Pharm Inc | Verbindungen modulierende thrombopoietinaktivität und verfahren |
| US7749530B2 (en) | 2005-07-13 | 2010-07-06 | Allergan, Inc. | Kinase inhibitors |
| CA2602389A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
| EP1902024B1 (en) * | 2005-07-13 | 2013-04-17 | Allergan, Inc. | Kinase inhibitors |
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
| WO2008022013A1 (en) | 2006-08-11 | 2008-02-21 | Allergan, Inc. | Kinase inhibitors |
| AU2007296740B2 (en) | 2006-09-11 | 2012-09-27 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
| WO2008033562A2 (en) | 2006-09-15 | 2008-03-20 | Xcovery, Inc. | Kinase inhibitor compounds |
| WO2008045627A2 (en) * | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| BRPI0808772A2 (pt) | 2007-03-14 | 2014-08-12 | Exelixis Inc | Inibidores da via de hedgehog |
| CA2703519C (en) | 2007-11-09 | 2017-04-18 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| EP2252612B1 (en) * | 2008-02-22 | 2012-03-28 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| JP5305704B2 (ja) * | 2008-03-24 | 2013-10-02 | 富士フイルム株式会社 | 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版 |
| JP2011520809A (ja) * | 2008-05-05 | 2011-07-21 | アムジエン・インコーポレーテツド | γセクレターゼモジュレーターとしての尿素化合物 |
| WO2009139834A1 (en) * | 2008-05-13 | 2009-11-19 | Poniard Pharmaceuticals, Inc. | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| CN102115472B (zh) * | 2010-01-04 | 2013-12-04 | 深圳市天和医药科技开发有限公司 | 3-(2-吡咯亚甲基)氮杂吲哚啉-2-酮衍生物及其制法与应用 |
| GB201014374D0 (en) * | 2010-08-27 | 2010-10-13 | Univ Greenwich | Novel hybrid compounds |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| IN2014MN02105A (no) * | 2012-04-20 | 2015-09-11 | Annji Pharm Co Ltd | |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| WO2014066840A1 (en) | 2012-10-26 | 2014-05-01 | Regents Of The University Of Minnesota | Aurora kinase inhibitors |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| US10487054B2 (en) | 2017-04-21 | 2019-11-26 | Regents Of The University Of Minnesota | Therapeutic compounds |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| CN118903436A (zh) | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| IL330104A (en) | 2019-03-11 | 2026-08-01 | Deciphera Pharmaceuticals Llc | Crystalline forms of rifatinib |
| US12691108B2 (en) | 2019-08-12 | 2026-07-28 | Deciphera Pharmaceuticals, Llc | Methods for treating vascular malformations |
| HRP20260411T1 (hr) | 2019-08-12 | 2026-05-08 | Deciphera Pharmaceuticals, Llc | Ripretinib za liječenje gastrointestinalnih stromalnih tumora |
| CN114846012B (zh) | 2019-09-27 | 2024-01-26 | 武田药品工业株式会社 | 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 |
| FI4084779T3 (fi) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| CN114853735B (zh) * | 2022-07-06 | 2022-10-21 | 北京鑫开元医药科技有限公司 | 靶向泛素化降解trk的化合物及其制备方法、组合物和用途 |
| CN114853736B (zh) * | 2022-07-06 | 2022-10-21 | 北京鑫开元医药科技有限公司 | 具有trk抑制活性的化合物、制备方法、组合物及其用途 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US20260069610A1 (en) | 2022-09-09 | 2026-03-12 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
| CN118221652B (zh) * | 2022-12-19 | 2025-06-06 | 沈阳药科大学 | 一种吲哚-2-酮衍生物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| WO1999048868A2 (en) * | 1998-03-26 | 1999-09-30 | Sugen, Inc. | Heterocyclic classes of compounds for the modulating tyrosine protein kinase |
| DK1082302T3 (da) | 1998-05-28 | 2004-04-26 | Biogen Inc | En VLA-4-inhibitor: oMePUPA-V |
| KR100743287B1 (ko) * | 1998-05-29 | 2007-07-26 | 수젠, 인크. | 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제 |
| CA2383623A1 (en) | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
| KR20010101266A (ko) * | 1998-12-17 | 2001-11-14 | 프리돌린 클라우스너, 롤란드 비. 보레르 | Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌 |
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| HRP20020751B1 (hr) * | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| JP2003535847A (ja) * | 2000-06-02 | 2003-12-02 | スージェン・インコーポレーテッド | 蛋白質キナーゼ/ホスファターゼ阻害剤としてのインドリノン誘導体 |
| US20030119839A1 (en) | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
| TW200301123A (en) * | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| AU2003302665B2 (en) * | 2002-11-15 | 2009-12-24 | Symphony Evolution, Inc. | Kinase modulators |
-
2005
- 2005-11-04 GT GT200500321A patent/GT200500321A/es unknown
- 2005-11-07 AU AU2005304719A patent/AU2005304719B2/en not_active Ceased
- 2005-11-07 US US11/718,886 patent/US8101608B2/en not_active Expired - Fee Related
- 2005-11-07 BR BRPI0517968-8A patent/BRPI0517968A/pt not_active IP Right Cessation
- 2005-11-07 KR KR1020077010439A patent/KR20070084066A/ko not_active Abandoned
- 2005-11-07 JP JP2007540153A patent/JP4917041B2/ja not_active Expired - Fee Related
- 2005-11-07 RU RU2007121505/04A patent/RU2406725C2/ru not_active IP Right Cessation
- 2005-11-07 EP EP05851419A patent/EP1814545A4/en not_active Withdrawn
- 2005-11-07 AR ARP050104664A patent/AR053652A1/es unknown
- 2005-11-07 WO PCT/US2005/040372 patent/WO2006052936A2/en not_active Ceased
- 2005-11-07 CA CA2583737A patent/CA2583737C/en not_active Expired - Fee Related
- 2005-11-07 MX MX2007005547A patent/MX2007005547A/es active IP Right Grant
- 2005-11-08 TW TW094139176A patent/TW200631577A/zh unknown
-
2007
- 2007-04-19 IL IL182687A patent/IL182687A0/en unknown
- 2007-05-08 TN TNP2007000176A patent/TNSN07176A1/fr unknown
- 2007-05-30 MA MA29953A patent/MA29216B1/fr unknown
- 2007-06-06 NO NO20072887A patent/NO20072887L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR053652A1 (es) | 2007-05-16 |
| MX2007005547A (es) | 2007-07-05 |
| WO2006052936A2 (en) | 2006-05-18 |
| EP1814545A2 (en) | 2007-08-08 |
| RU2406725C2 (ru) | 2010-12-20 |
| EP1814545A4 (en) | 2009-06-10 |
| JP2008519762A (ja) | 2008-06-12 |
| TW200631577A (en) | 2006-09-16 |
| TNSN07176A1 (en) | 2008-11-21 |
| WO2006052936A3 (en) | 2006-10-26 |
| CA2583737A1 (en) | 2006-05-18 |
| CA2583737C (en) | 2011-09-20 |
| KR20070084066A (ko) | 2007-08-24 |
| US8101608B2 (en) | 2012-01-24 |
| US20080221192A1 (en) | 2008-09-11 |
| AU2005304719B2 (en) | 2009-07-23 |
| GT200500321A (es) | 2006-09-04 |
| BRPI0517968A (pt) | 2008-10-21 |
| JP4917041B2 (ja) | 2012-04-18 |
| MA29216B1 (fr) | 2008-02-01 |
| AU2005304719A1 (en) | 2006-05-18 |
| RU2007121505A (ru) | 2008-12-20 |
| IL182687A0 (en) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07176A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| MX2009003649A (es) | Inhibidores de cinasa de proteina y metodos para utilizarlos. | |
| NO20070160L (no) | Forbindelser og sammensetninger som proteinkinaseinhibitorer | |
| TW200726766A (en) | Compounds and compositions as protein kinase inhibitors | |
| ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
| MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| WO2006101783A8 (en) | Compounds and compositions as protein kinase inhibitors | |
| NO20092612L (no) | Forbindelser og metode for kinasemodulering og indikasjoner for dette | |
| PL1940844T3 (pl) | Związki i kompozycje jako inhibitory kinazy białkowej | |
| ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
| NO20092138L (no) | Forbindelser og sammensetninger som proteinkinase inhibitorer | |
| BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
| NO20091989L (no) | Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse | |
| BR0313562A (pt) | derivados de indol ou benzimidazol para a modulação da ikb-cinase | |
| NO20084567L (no) | Polymorfe former av (2S) - (4E) -N-metyl-5-(3-isopropoksypyridin)yl]-4-penten-2-amin for behandling av sykdommer i sentralnervesystemet | |
| MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
| NO20082679L (no) | Sammensetning og fremgangsmate for a behandle CNS lidelser | |
| NO20065983L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
| NO20092073L (no) | Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav | |
| BRPI0414049A (pt) | compostos e composições como inibidores de proteìna cinase | |
| NO20071466L (no) | 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |